BMY 10-K Analysis: The $16B Earnings Recovery Is a GAAP Mirage

Bristol-Myers Squibb, a $48.2 billion biopharmaceutical company navigating the industry's largest patent cliff, just reported the most dramatic earnings swing in its history — net income reversed from a $8.9 billion loss to a $7.1 billion profit. But free cash flow declined 7.9% to $12.8 billion.

Wall Street celebrated the headline: earnings per share swung from -$4.41 to +$3.47, a $7.88 reversal that ranks among the largest in pharma history. Analysts pointed to revenue holding steady at $48.2 billion and the Growth Portfolio accelerating at +17% year-over-year. The "earnings recovery" narrative took hold immediately, with several sell-side upgrades following the February 2026 release. But dig into the 10-K's footnotes and cash flow statement, and a fundamentally different story emerges — one where the recovery is an accounting illusion, the patent cliff is already compressing revenue two years ahead of schedule, and the market may be right to price BMY as a controlled decline story.

The real signal is in what the 10-K reveals about three simultaneous compression vectors — IRA pricing, an unprecedented government trade agreement, and EU generics already on the market — that are converging on BMY's revenue base faster than the market's 2028 patent cliff timeline implies. At 11.7% free cash flow yield, Bristol-Myers Squibb is either the most undervalued cash generator in large-cap pharma, or the market has correctly priced in an earnings trajectory that GAAP accounting is temporarily disguising.

The $16B Earnings Mirage

The headline numbers tell a compelling story: GAAP earnings per share went from -$4.41 to +$3.47, operating income swung by $17.7 billion, and net income reversed from -$8.9 billion to +$7.1 billion. For any company, this would look like a dramatic turnaround. For Bristol-Myers Squibb, it is almost entirely a non-cash accounting event — and the two most common earnings frameworks tell opposite stories about what happened in 2025.

The engine of the "recovery" was a single line item: depreciation and amortization collapsed from $9,600 million to $4,011 million, a $5,589 million decline (-58%). This happened because the acquired intangible asset associated with Revlimid — the blockbuster blood cancer drug BMY obtained through its $74 billion Celgene acquisition in 2019 — was fully amortized by Q4 2024. When a multi-billion-dollar amortization charge rolls off the income statement, GAAP earnings surge mechanically, without any change in the underlying business. Impairment charges also dropped from $2,900 million to $949 million, adding another $1,951 million to the operating income swing.

The complication becomes visible when you flip to Non-GAAP earnings, management's preferred framework. Non-GAAP EPS strips out the amortization charges, so the Revlimid rolloff should be invisible. Yet Non-GAAP EPS also declined — from approximately $6.70-$7.00 in FY2024 to $6.15 in FY2025, a drop of $0.55-$0.85. Why? Because $3,721 million in Acquired IPRD charges flowed through the Non-GAAP reconciliation. The GAAP framework shows a dramatic recovery driven by amortization; the Non-GAAP framework shows modest deterioration driven by pipeline investments. Neither framework tells the cash flow story accurately.

Free cash flow — the amount of cash the business actually generates after maintaining its operations — declined 7.9% from $13,942 million to $12,845 million. The operating cash flow to net income ratio hit 2.01x, an anomalously high multiple that signals non-cash items are dominating the income statement rather than cash-generating operations improving. This ratio is the fingerprint of an earnings mirage: when OCF/NI is well above 1.5x, it typically means a large non-cash charge reversal (in this case, amortization) inflated GAAP net income without producing a corresponding increase in cash.

For investors, the implication is direct: anyone anchoring their BMY thesis to the earnings recovery is anchoring to an accounting artifact. Bristol-Myers Squibb's net income swung $16 billion in FY2025, but free cash flow declined 7.9% to $12.8 billion because the entire earnings recovery was a non-cash accounting event — acquired intangible amortization dropping $5.6 billion as the Celgene purchase price finished expensing. The only reliable signal for the underlying business is cash flow, and it moved in the wrong direction.

Three-Vector Revenue Compression

Most patent cliff analysis treats the Eliquis expiration as a single event anchored to April 2028, when U.S. generic entry becomes legally possible. The 10-K reveals something more complex and more immediate: three independent compression vectors are already operating, each attacking BMY's revenue from a different direction and through a different mechanism. The patent cliff is not a cliff at all — it is a gradient that started in 2025.

The most consequential vector is the U.S. Government Agreement, disclosed in the risk factors section and unlike anything the pharmaceutical industry has seen before.

"In December 2025, we announced the U.S. Government Agreement pursuant to which we agreed to, among other things: (i) provide Eliquis for free to the Medicaid program effective January 1, 2026; (ii) donate more than seven tons of Eliquis API to fill the U.S. Strategic Active Ingredient Reserve; (iii) enable direct-to-patient access to Sotyktu, Zeposia, Reyataz, Baraclude and Orencia for cash-paying patients at discounts approximately 80% off current list prices"

In exchange, BMY receives tariff relief until January 2029 and exemption from future pricing mandates. The strategic logic is rational — for a company managing a $14.7 billion patent cliff, removing policy uncertainty has quantifiable value. But the revenue sacrifice is substantial. If Medicaid represents approximately 15-20% of U.S. Eliquis volume (estimated at $10 billion in U.S. sales), the free-supply provision could reduce Eliquis revenue by $1.5-2.0 billion annually. The 80% discounts on five other products likely add $200-500 million. Total estimated annual revenue sacrifice: $1.7-2.5 billion, which largely explains why 2026 revenue is guided down to $46.0-$47.5 billion despite the Growth Portfolio's continued momentum.

The second vector is IRA pricing, which is escalating faster than the market anticipated:

"In August 2024, as part of the first round of government price setting pursuant to the IRA, the HHS announced the 'maximum fair price' for a 30-day equivalent supply of Eliquis, which applies to the U.S. Medicare channel effective January 1, 2026. In November 2025, the HHS announced the 'maximum fair price' for a 30-day supply of Pomalyst, which applies to the U.S. Medicare channel effective January 1, 2027. In January 2026, the HHS selected Orencia as a medicine subject to 'negotiation' for government-set prices beginning in 2028."

Three BMY products selected for government-set pricing in 18 months. Eliquis and Pomalyst are Legacy Portfolio drugs already in decline, but Orencia is a Growth Portfolio product generating $2.9 billion in annual revenue. IRA pricing has now crossed the firewall between Legacy and Growth, meaning the regulatory headwind extends beyond the patent cliff into the products that are supposed to bridge through it. Average U.S. net selling prices already declined 4% in FY2025, and gross-to-net adjustments increased from Medicare Part D program redesign.

The third vector is geographic erosion. The 10-K confirms that generic Eliquis has already launched in the UK and Finland following adverse patent court decisions, with the filing warning that manufacturers "may seek to market generic versions of Eliquis in additional countries in Europe, prior to the expiration of our patents." International revenue represented 31% of BMY's total ($14.9 billion), and international Eliquis revenue is estimated at approximately $4.3 billion. EU generic erosion at even modest penetration rates could reduce international Eliquis revenue by $0.5-1.5 billion by 2027.

A critical nuance: the IRA targets the Medicare channel while the Government Agreement targets the Medicaid channel. These are largely separate federal payer programs, making the first two vectors mostly additive rather than overlapping. The One Big Beautiful Bill Act (OBBBA), enacted in July 2025, adds yet another Medicaid headwind layer whose full scope BMY is "continuing to assess." The $3.2-6.0 billion combined range is directional, with overlap risk estimated at 10-15% given the separate payer mechanisms.

Bristol-Myers Squibb faces $3.2-6.0 billion in annual revenue compression from IRA pricing, a government trade deal providing Eliquis free to Medicaid, and EU generics already launched — all before the 2028 U.S. patent cliff date the market focuses on. The 2026 guidance decline of $0.7-2.2 billion is not a one-year event but the beginning of a multi-year compression gradient that transforms the binary cliff model into something far more nuanced and already underway.

The Cash Flow Paradox

Bristol-Myers Squibb presents an anomaly that should give every pharma investor pause: it simultaneously generates the highest free cash flow yield in large-cap pharma and the lowest return on invested capital among peers. Both metrics trace to the same cause, and understanding their interaction is the key to determining whether BMY is dramatically undervalued or correctly priced.

At 11.7%, BMY's FCF yield is 2.5 times Merck's 4.7% and nearly double Gilead's 6.2%. In absolute terms, BMY generates $12.8 billion in free cash flow — essentially the same as Merck's $12.4 billion — but at a market capitalization of $109.7 billion versus Merck's $263.4 billion. The market values BMY's cash stream at roughly half the multiple it assigns to Merck's, implying a fundamental belief that BMY's cash generation is temporary or impaired.

The ROIC paradox resolves when you trace it to the $74 billion Celgene acquisition. The deal loaded $40.9 billion in goodwill and intangible assets onto BMY's balance sheet, inflating the invested capital denominator that drives ROIC calculations. At 10.9%, BMY's ROIC sits well below Merck's 20.7% and Gilead's 18.6%. But Cash ROIC — which strips out the non-cash amortization overhang and uses cash earnings — comes in at 24.5%, revealing that the underlying operating business generates substantially higher returns on real capital than the GAAP metric suggests. As the remaining intangibles continue amortizing (Pomalyst's intangible fully amortized in Q4 2025, with $3,317 million remaining across other assets), the book value distortion will continue shrinking.

However, the return on incremental invested capital (ROIIC) tells a more cautionary story. At -4.65 on a trailing twelve-month basis, ROIIC indicates that BMY's recent capital deployments — the RayzeBio, Mirati, and Karuna acquisitions — have not yet generated proportional cash returns. This is expected for early-stage pipeline assets, but it means the "high FCF yield" argument depends entirely on the legacy cash flows from products that face the compression gradient discussed above.

The capital allocation strategy reflects management's awareness of this tension. BMY has committed to zero share buybacks, directing all excess cash to deleveraging. Total debt declined from $48.9 billion to $45.1 billion, with a sophisticated refinancing that redeemed approximately $8.0 billion in high-coupon USD debt (weighted average ~5.2% coupon, including 6.25% and 6.40% long-dated notes) and issued $5.9 billion in new Euro-denominated notes at a weighted average of ~3.8%. The $356 million loss on early redemption was a one-time cost for estimated annual interest savings of $100-120 million, while Euro-denominated debt provides a natural currency hedge for BMY's 31% international revenue base. S&P downgraded BMY from A+ to A, but the trajectory is clearly toward deleveraging rather than further leverage.

"Manufacturing processes for novel cell-based therapies, such as CAR-T cell therapies, and radiopharmaceutical therapeutics in development are still evolving, and our processes may be more complicated or more expensive than the approaches taken by our current and future competitors."

The dividend remains well-covered at 2.55x by FCF ($12,845 million FCF versus $5,045 million in dividends), with 17 consecutive annual increases. Even under a stress scenario — revenue falling to $46 billion with FCF margin compressing to 20% from 26.7% — FCF of approximately $9.2 billion would still cover dividends at 1.82x. But the CAR-T and radiopharmaceutical manufacturing disclosure matters for the longer term: as the revenue mix shifts from high-margin Legacy small molecules toward Growth Portfolio products with structurally higher cost of goods, FCF margins face compression even if revenue holds steady.

Bristol-Myers Squibb generates an 11.7% free cash flow yield — 2.5 times Merck's 4.7% — making it the cheapest large-cap pharma on a cash-flow basis despite its $45 billion debt load. Whether that yield is a screaming buy signal or will compress toward the 4-6% peer range as revenue declines and COGS rise is the central investment question.

The Replacement Race

The Growth Portfolio must roughly double from $26.4 billion by 2030 to replace what is at risk. Understanding why requires one critical fact that financial media frequently mischaracterizes: Eliquis, BMY's largest product at an estimated $14.7 billion in FY2025 revenue, is classified in the Legacy Portfolio — not the Growth Portfolio. This single drug represents 30.5% of total revenue and 67% of the entire Legacy Portfolio. When analysts discuss the "patent cliff," they are largely discussing one product.

The Legacy Portfolio ($21.8 billion, -15% year-over-year) is essentially the Eliquis Portfolio: beyond Eliquis's $14.7 billion, Revlimid contributes approximately $2.6 billion, Pomalyst $2.5 billion, and the remainder is split across declining products like Sprycel and Abraxane. All face some form of loss of exclusivity within the next five years.

The Growth Portfolio ($26.4 billion, +17%) carries the full weight of the replacement burden. Opdivo anchors at approximately $6.1 billion with stable but not accelerating growth. Orencia, Yervoy, and Reblozyl collectively contribute about $8.1 billion. The fastest growers — Breyanzi at +82% and Camzyos at +77% — generate exciting growth rates but from small bases: combined, they produced approximately $2.9 billion in annualized run-rate revenue. Together with Cobenfy (schizophrenia, in early launch at approximately $0.8 billion annualized), the three highest-growth products represent about $3.7 billion — roughly 25% of what Eliquis alone generates. The math of small-base scaling is daunting: even at 50% annual growth, Breyanzi would need five years to approach $10 billion, and CAR-T therapy market dynamics typically produce S-curves that flatten well before then.

Management's response to this math problem is aggressive pipeline reinvestment. FY2025's $3,721 million in Acquired IPRD charges represented 7.7% of revenue — a strikingly high rate of pipeline investment for a single year. This included $1,508 million for the BioNTech bispecific partnership (pumitamig), plus investments in Orbital Therapeutics (in vivo CAR-T for autoimmune), Philochem (OncoACP3 radiopharmaceutical), and other licensing deals. The revenue guidance trajectory in 2025 reveals management's priorities clearly: revenue was raised three consecutive times (from $45.8-$46.8 billion initially to $48.2 billion actual), while EPS guidance was cut three consecutive times (from $6.70-$7.00 to $6.15 actual). The revenue beat funded the pipeline investment that caused the EPS miss. This is a quality-of-miss signal — management chose long-term pipeline depth over short-term EPS guidance in the face of a $14.7 billion patent cliff.

The complication is margin structure. The 10-K's risk factors explicitly acknowledge that CAR-T and radiopharmaceutical manufacturing processes "may be more complicated or more expensive" than competitors. Q4 2025 data already hints at this: non-GAAP gross margin was approximately 71.9% in Q4 versus 72.6% for the full year, a modest sequential compression that coincides with Breyanzi and Camzyos growing as revenue share. As the product mix shifts from high-margin Legacy small molecules toward Growth Portfolio biologics and cell therapies, the Growth Portfolio will need to generate higher revenue than the Legacy drugs it replaces to produce equivalent free cash flow. Management's $2.0 billion cost savings target by end-2027 partially addresses this, but structural COGS inflation from product mix remains a headwind.

Bristol-Myers Squibb's Growth Portfolio must roughly double from $26.4 billion to replace the $14.7 billion Eliquis franchise and other declining legacy drugs — a race management is funding at $3.7 billion per year in pipeline acquisitions that deliberately caused an earnings miss. The question is not whether the Growth Portfolio can grow — it clearly can, at 17% — but whether it can grow fast enough, with sufficient margin, to maintain the $12.8 billion cash flow engine that makes BMY's valuation case work.

What to Watch

At $53.94 and 2.28x trailing revenue, the market implies a roughly $24 billion permanent revenue reduction — approximately consistent with losing Eliquis ($14.7 billion) and Revlimid ($2.6 billion) with zero replacement value priced in. The filing evidence suggests the decline starts earlier than the market's 2028 anchor (compression is already underway in 2026), but the cash flow engine is more resilient than the stock price implies: even a 30% decline in free cash flow would produce an 8.2% yield, still above every pharma peer.

The thesis — that BMY's earnings recovery is a mirage while compression vectors converge faster than the market expects — will be tested by four specific metrics over the next two quarters:

1. Q1 2026 Eliquis Revenue — This is the first quarter with both IRA maximum fair pricing (Medicare) and free Medicaid supply under the Government Agreement. A decline greater than 25% from the approximately $3.8 billion quarterly run rate confirms front-loaded compression and puts 2026 guidance low-end ($46.0 billion) at risk. Revenue above $3.4 billion would signal the Government Agreement's impact is smaller than estimated — bullish for FCF sustainability.

2. Growth Portfolio Quarterly Run-Rate — Sustaining above $7.0 billion (seasonally adjusted from Q4's $7.4 billion) confirms the replacement rate is on track. A drop below $6.5 billion would signal seasonal effects or Cobenfy launch weakness, raising the replacement timeline risk. Above $7.2 billion would suggest Growth products are absorbing volume from Government Agreement-related channel shifts.

3. Non-GAAP Gross Margin — If non-GAAP gross margin dips below 71% (from 72.6% full-year and 71.9% in Q4), it confirms the CAR-T/RPT COGS mix shift is structurally compressing margins as Growth Portfolio products gain revenue share. This is the margin signal that determines whether the Growth Portfolio can replace Legacy FCF or only Legacy revenue.

4. Acquired IPRD Charges — Normalization below $500 million per quarter signals management has confidence in the internal pipeline (milvexian, existing readouts). Continuation above $800 million signals ongoing need for external assets and further EPS pressure, but also more aggressive cliff-preparation.

At 11.0x EV/EBITDA and an 11.7% FCF yield, the market prices BMY as a controlled decline story. The filing supports this framing but complicates it: the decline starts earlier (three vectors in 2026, not one in 2028), the cash engine is stronger than the GAAP earnings suggest (Cash ROIC 24.5% versus GAAP ROIC 10.9%), and management is making a deliberate bet on pipeline depth over near-term earnings. Whether you view the 11.7% FCF yield as a margin of safety or a yield trap depends on one variable: the speed and margin profile of the Growth Portfolio's replacement of Eliquis. The 10-K provides the map. Q1 2026 earnings will provide the first real test.

Frequently Asked Questions

Did Bristol-Myers Squibb's earnings really recover in 2025?

Only on a GAAP basis. Net income swung from -$8.9 billion to +$7.1 billion (EPS -$4.41 to +$3.47), but the entire swing came from non-cash items: depreciation and amortization dropped $5.6 billion (-58%) as Revlimid's acquired intangible fully amortized, and impairment charges dropped $2.0 billion. Free cash flow actually declined 7.9% from $13.9 billion to $12.8 billion. Non-GAAP EPS declined approximately $0.55-$0.85 year-over-year. The two accounting frameworks tell opposite stories about 2025.

What is BMY's U.S. Government Agreement and how does it affect revenue?

In December 2025, BMY entered an unprecedented agreement to provide Eliquis free to Medicaid starting January 1, 2026, donate more than seven tons of Eliquis API to the U.S. Strategic Reserve, and offer approximately 80% discounts on five other products to cash-paying patients. In exchange, BMY receives tariff relief through January 2029 and exemption from future U.S. pricing mandates. The estimated annual revenue sacrifice is $1.7-2.5 billion, largely explaining why 2026 revenue is guided down to $46.0-$47.5 billion despite the Growth Portfolio's continued momentum.

Is BMY's dividend safe through the patent cliff?

Yes, based on current cash flow. Free cash flow of $12.8 billion covers the $5.0 billion annual dividend at 2.55x. Even under a stress scenario — revenue at $46 billion (2026 guidance low end) with FCF margin compressing to 20% from 26.7% — FCF would be approximately $9.2 billion, still covering dividends at 1.82x. BMY has raised the dividend 17 consecutive years. The risk is not near-term dividend sustainability but whether FCF margins compress faster than modeled as Growth Portfolio COGS from CAR-T and radiopharmaceutical manufacturing structurally exceed Legacy Portfolio margins.

How does BMY's valuation compare to pharma peers?

BMY trades at a significant discount on every valuation metric: 11.0x EV/EBITDA versus Merck at 11.6x, Gilead at 16.3x, and Abbott at 23.5x. Its FCF yield of 11.7% is 2.5 times Merck's 4.7% and the highest in large-cap pharma. At $53.94, BMY generates comparable absolute free cash flow ($12.8 billion versus Merck's $12.4 billion) at less than half the market capitalization ($109.7 billion versus Merck's $263.4 billion). The discount reflects the market pricing Eliquis patent cliff risk — 30.5% of revenue is a single drug facing loss of exclusivity — and $45.1 billion in acquisition debt from the Celgene deal.

What is the IRA's impact on BMY's drug portfolio?

Three BMY products have been selected for IRA government-set pricing within 18 months: Eliquis (maximum fair price effective January 2026 for Medicare), Pomalyst (effective January 2027), and Orencia (selected for 2028 negotiation). Critically, Orencia is a Growth Portfolio product generating $2.9 billion in annual revenue, meaning IRA pricing pressure now extends beyond the Legacy Portfolio into the products that are supposed to bridge BMY through the patent cliff. Average U.S. net selling prices already declined 4% in FY2025, and gross-to-net adjustments increased from Medicare Part D program redesign.

How much did BMY spend on pipeline investments in 2025?

BMY recorded $3,721 million in Acquired IPRD charges in FY2025, representing 7.7% of revenue invested in pipeline assets in a single year. The largest charge was $1,508 million for the BioNTech bispecific partnership (pumitamig), with additional charges for Orbital Therapeutics (in vivo CAR-T for autoimmune), Philochem (radiopharmaceutical), and other licensing deals. This investment rate was high enough to cause a Non-GAAP EPS miss ($6.15 actual versus $6.40-$6.60 guided), but revenue beat every guidance update — management raised revenue guidance three consecutive times before choosing pipeline depth over short-term earnings.

What is the Eliquis patent timeline?

The cliff is not a single 2028 event but a rolling compression that started in 2025. EU generics launched in the UK and Finland in late 2025 following adverse patent court decisions. IRA maximum fair price for Medicare took effect January 1, 2026. Free Eliquis to Medicaid under the Government Agreement also started January 1, 2026. U.S. generic entry is expected in April 2028 based on patent expiry. Eliquis generated an estimated $14.7 billion in FY2025, or 30.5% of total revenue. By the time U.S. generics arrive, international and government-channel erosion will have already significantly compressed Eliquis revenue from its peak.

How is BMY managing its $45 billion debt load?

BMY executed a sophisticated refinancing in FY2025: it redeemed approximately $8.0 billion in high-coupon USD debt at a weighted average coupon of roughly 5.2% (including 6.25% and 6.40% long-dated notes) and issued approximately $5.9 billion in new Euro-denominated debt at lower rates (weighted average roughly 3.8%). Net debt repayment was approximately $4.6 billion, reducing total debt from $48.9 billion to $45.1 billion. The $356 million loss on early debt redemption was a one-time cost for estimated annual interest savings of $100-120 million. Euro-denominated issuance also provides a natural currency hedge for BMY's 31% international revenue base. S&P downgraded BMY from A+ to A due to acquisition-related leverage, but the deleveraging trajectory is clear.

Why does BMY have the highest FCF yield but lowest ROIC among peers?

Both anomalies trace to the $74 billion Celgene acquisition (closed 2019). The $40.9 billion in goodwill and intangible assets inflates the invested capital denominator, mechanically depressing ROIC to 10.9% versus Merck's 20.7% and Gilead's 18.6%. But the acquired products — especially Revlimid and the cell therapy platform — generate substantial operating cash flow, supporting $12.8 billion in free cash flow and the 11.7% yield. Cash ROIC, which uses cash earnings, comes in at 24.5%, revealing that the underlying business generates strong returns when stripping out the non-cash amortization overhang. As intangibles continue amortizing and debt is repaid, ROIC should converge toward peers — if the Growth Portfolio maintains revenue.

What are BMY's fastest-growing products?

Breyanzi (CAR-T therapy, +82% year-over-year to approximately $1.5 billion annualized) and Camzyos (cardiac myosin inhibitor, +77% to approximately $1.4 billion annualized) are the standout performers. Breyanzi received 5 FDA approvals in 2025, giving it the broadest label of any CAR-T therapy. Cobenfy (schizophrenia, launched late 2024) is in early launch ramp at approximately $0.8 billion annualized. However, the math of small-base scaling is challenging: combined, Breyanzi, Camzyos, and Cobenfy represent approximately $3.7 billion — about 25% of what Eliquis alone generates at $14.7 billion. The Growth Portfolio needs to roughly double by 2030 to fully replace at-risk revenue.

What are BMY's Growth and Legacy Portfolios?

BMY uniquely discloses revenue in two categories. The Growth Portfolio ($26.4 billion, +17% year-over-year, 55% of revenue) includes Opdivo, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, and Cobenfy. The Legacy Portfolio ($21.8 billion, -15% year-over-year, 45% of revenue) includes Eliquis (approximately $14.7 billion), Revlimid (approximately $2.6 billion), Pomalyst (approximately $2.5 billion), Sprycel, and Abraxane. A critical detail: Eliquis is classified as Legacy despite being BMY's single largest product — it alone represents 67% of the entire Legacy Portfolio.

What should investors watch for in BMY's Q1 2026 earnings?

Three metrics will test the thesis: (1) Eliquis quarterly revenue — the first quarter with both IRA maximum fair pricing and free Medicaid supply; a decline greater than 25% from the approximately $3.8 billion quarterly run rate confirms front-loaded compression and puts 2026 guidance at risk. (2) Growth Portfolio run-rate — sustaining above $7 billion confirms the replacement pace is on track. (3) Non-GAAP gross margin trend — if it dips below 71% from 72.6% full-year, it confirms that CAR-T and radiopharmaceutical manufacturing COGS are pressuring margins as the product mix shifts, which would mean the Growth Portfolio needs even more revenue to generate equivalent free cash flow.

Methodology

Data Sources

This analysis is based on Bristol-Myers Squibb's FY2025 Annual Report (10-K), filed February 11, 2026, and the Q4 FY2025 8-K earnings release filed February 5, 2026. Core financial metrics (income statement, balance sheet, cash flow, returns, valuation multiples) are derived from the MetricDuck automated pipeline, which processes XBRL filings from SEC EDGAR. Peer data for MRK, GILD, ABT, and ISRG is sourced from the same pipeline using FY2025 annual filings (ISRG uses TTM data as of Q3 2025). Filing text quotes are extracted verbatim from the risk factors and narrative intelligence sections.

Limitations

• Eliquis revenue is estimated. BMY does not disclose annual Eliquis revenue in the 10-K; the approximately $14.7 billion figure is derived from 8-K quarterly product tables and may differ from the precise annual total.
• Government Agreement revenue impact is an estimate. The $1.7-2.5 billion range assumes Medicaid represents 15-20% of U.S. Eliquis volume; the actual Medicaid channel share is not publicly disclosed.
• The three-vector compression model uses estimated ranges. Individual vector impacts ($1.0-2.0B, $1.7-2.5B, $0.5-1.5B) target largely separate payer channels (Medicare vs. Medicaid vs. EU) but some overlap exists, particularly at the margins. The combined $3.2-6.0 billion range is directional.
• COGS mix shift impact is directional, not precisely quantified. The filing states CAR-T manufacturing may be more expensive but does not provide product-level cost of goods data. Margin compression is inferred from Q4 versus full-year differentials.
• Peer comparison uses different fiscal years. ISRG data is trailing twelve months as of Q3 2025, while others are FY2025. ISRG's 22% growth rate means TTM data may understate current performance.
• Forward-looking projections are testable predictions, not forecasts. Tracking metrics and thresholds are designed to be falsified by Q1 2026 earnings data and should not be treated as investment targets.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in BMY, MRK, GILD, ABT, or ISRG. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process. Investors should conduct their own due diligence and consult with qualified financial advisors before making investment decisions.